Cellectar registers Phase 3 trial comparing iopofosine I 131 to R-CD in Waldenstrom's
Cellectar Biosciences listed a new Phase 3 study testing iopofosine I 131 against a rituximab-based regimen in Waldenstrom Macroglobulinemia patients who progressed after BTK inhibitor treatment.
Cellectar Biosciences had one registry update this week, a newly listed Phase 3 trial.
- Iopofosine I 131 (also called CLR 131), Phase 3, Waldenstrom Macroglobulinemia: registered as "not yet recruiting" on 2026-08-14. The trial is designed to demonstrate superiority of progression free survival of iopofosine I 131 compared with the combination of rituximab, cyclophosphamide, and dexamethasone in patients with WM who have relapsed or are refractory to a Bruton tyrosine kinase inhibitor1. The study plans to enroll up to 219 evaluable patients1, with an estimated start in 2026-12 and primary completion in 2032-01.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.